Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Novozymes A/S (NVZMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
62.37+2.27 (+3.78%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close60.10
Open62.28
BidN/A x N/A
AskN/A x N/A
Day's Range61.84 - 62.57
52 Week Range57.85 - 83.31
Volume18,743
Avg. Volume18,546
Market Cap17.253B
Beta (5Y Monthly)0.28
PE Ratio (TTM)39.68
EPS (TTM)1.57
Earnings DateN/A
Forward Dividend & Yield0.82 (1.31%)
Ex-Dividend DateMar 17, 2022
1y Target Est70.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NVZMY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NOVOZYMES A/S UNSP ADR EACH REP
    Analyst Report: Coloplast A/SColoplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy-care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and wound-care markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
    Rating
    Fair Value
    Economic Moat
    13 days agoMorningstar
View more
  • GlobeNewswire

    Novozymes delivers strong 2022 Q1 results and raises full-year financial guidance

    Novozymes delivered solid earnings and double-digit organic sales growth in the first quarter of 2022. Despite negative effects of the tragic war in Ukraine the company increases its full-year organic sales growth from 3-7% to now 4-8%. COPENHAGEN, Denmark – April 26, 2022. With 10% organic sales growth (16% sales growth in DKK) and an EBIT-margin of 26.1% in Q1, Novozymes is off to a solid start to the year. Good momentum and strong Q1 results have led to an increased organic sales growth outlo

  • GlobeNewswire

    Novozymes announces plan to increase prices to cover rising cost of raw materials, energy, and logistics

    Novozymes has experienced unprecedented inflation on raw materials, energy, and logistics. To recover these headwinds price increases will be implemented. COPENHAGEN, Denmark – March 31st, 2022. Today Novozymes announces its plan to pass on the incurred increase in raw material, energy, and logistics costs to its customers across geographies and industries. Over the past six months, Novozymes has experienced unprecedented inflation on raw materials and this initiative is put in place to recover

  • GlobeNewswire

    Novozymes delivers strong 2021 full-year results and expects continued, solid progress in 2022

    Novozymes is executing on its strategic framework by delivering 6% organic sales growth for 2021 and presenting a solid organic growth outlook of 3-7% for 2022. The company is also on track to meet its ambitious non-financial targets and deliver on its plan to enable a healthier planet. COPENHAGEN, Denmark – February 1, 2022. In the 2021 financial year, Novozymes delivers 6% organic sales growth – 7% organic sales growth in the fourth quarter alone – an EBIT-margin of 26.8%, and ROIC including g

Advertisement
Advertisement